SCHEMBL4118522

SCHEMBL4118522

CCOC(=S)C(C#N)=C(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 7/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 3/20 0.34
PKM P14618 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MAPK1 P28482 2/20 0.34
HTT P42858 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10573503 0.84 HPGD (0.38) KMT2AKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL9760357 0.82 KMT2A (0.48) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL7496103 0.77 ALDH1A1 (0.50) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL11256579 0.77 KMT2A (0.46) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL11256576 0.77 KMT2A (0.46) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL3251246 0.75 ALDH1A1 (0.44) MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL7493239 0.74 ALDH1A1 (0.45) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL25883387 0.73 KMT2A (0.48) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL9279794 0.73 KMT2A (0.48) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL7329984 0.72 CES2 (0.55) MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD MEN1 1656/4885KMT2A 2532/4885HSD17B10 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.